Quetiapine Fumarate
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Psychosis
Conditions
Psychosis
Trial Timeline
Jul 1, 2003 → Jan 1, 2006
NCT ID
NCT00449397About Quetiapine Fumarate
Quetiapine Fumarate is a phase 3 stage product being developed by AstraZeneca for Psychosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00449397. Target conditions include Psychosis.
What happened to similar drugs?
3 of 16 similar drugs in Psychosis were approved
Approved (3) Terminated (1) Active (13)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (14)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00498628 | Phase 2 | Completed |
| NCT00370500 | Approved | Completed |
| NCT00326105 | Phase 3 | Completed |
| NCT00326144 | Phase 3 | Completed |
| NCT00329264 | Phase 3 | Completed |
| NCT00320268 | Phase 3 | Completed |
| NCT00122070 | Phase 3 | Completed |
| NCT00314184 | Phase 3 | Completed |
| NCT00227305 | Phase 3 | Completed |
| NCT00304473 | Phase 3 | Completed |
| NCT00090311 | Phase 3 | Completed |
| NCT00085891 | Phase 3 | Completed |
| NCT00083954 | Phase 3 | Completed |
| NCT00449397 | Phase 3 | Completed |
Competing Products
20 competing products in Psychosis